Psychedelics
DMT (dimethyltryptamine)
Street names: The Spirit Molecule, Deems, Dimitri, Businessman's trip
Overdose? Act now. Call emergency services — say "unresponsive, not breathing". Give naloxone for opioid-like signs. Hotlines
⚡What it does
- 5–20 min intense visual hallucinations, entity encounters
- Altered sense of reality/time
- Euphoria or terror
⚠Key risks
- Psychological distress ('bad trips')
- Dangerous behavior if unprepared
- Raises heart rate/blood pressure
✚Overdose signs
- No known lethal overdose in pure form — but terror/panic attacks are common
- Fainting, vomiting
📋Quick facts
Also known asThe Spirit Molecule, Deems, Dimitri, Businessman's trip
CategoryPsychedelics
Schedule / classSchedule I (US)
AppearanceWhite/yellow crystalline powder; also in ayahuasca plant brews
Street price~$20–$60 per 50–100 mg dose
Legal statusSchedule I (US); Class A UK; controlled everywhere listed (plant/brew laws vary, e.g. religious exemptions in some countries)
Last updated2026-09-12
Sources: NIDA, DEA, MAPS
Category comparison — Psychedelics
| Substance | Class | Top risks | Street price |
|---|---|---|---|
| DMT (dimethyltryptamine) | Schedule I | Psychological distress ('bad trips'); Dangerous behavior if unprepared | ~$20–$60 per 50–100 mg dose |
| Peyote (mescaline cactus) | Schedule I | Severe nausea/vomiting; Psychological distress | ~$10–$30 per button where sold |
| Mescaline powder | Schedule I | Heavy nausea at dose; Panic/psychosis in vulnerable users | ~$20–$60 per dose |
| 2C-B | Schedule I | Very dose-sensitive — steep curve between fun and overwhelming; Panic attacks | ~$10–$30 per pill or ~$50–$120 per gram |
| 4-AcO-DMT (psilacetin) | Analogue prosecutions | Sold as 'legal mushrooms' — buyers misjudge dose; Panic, risky behavior | ~$20–$50 per dose |
Street prices are regional estimates. Potency and cuts vary constantly — see our pressed pill guide.
Spotted wrong or outdated info?
Profiles are reviewed against NIDA/DEA/EMCDDA sources. See something off? Submit a correction — it goes straight to our editorial queue.